Tarlatamab
from OncoPharm Hosted by John Bossaer
A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 10 minutes long.
When was this OncoPharm episode published?
This episode was published on May 23, 2024.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.